GlassScriptPhysician profile
Ernest Weeks
NPI 1134330822
$3,449.04
in general payments reported to CMS, 2019-2025
26 companies · $372 in 2025
The $372 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $627 · 2020: $537 · 2021: $486 · 2022: $438 · 2023: $446 · 2024: $543 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,361.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,294.96 | 2019-2024 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $512.77 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Abbvie INC. | $466.82 | 2019-2025 | Creon, Rinvoq, Skyrizi |
| Phathom Pharmaceuticals, INC. | $204.62 | 2023-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $175.52 | 2019-2024 | Linzess |
| Pfizer INC. | $142.11 | 2019 | |
| Medtronic, INC. | $133.13 | 2024 | Gi Genius |
| Celgene Corporation | $120.98 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $48.66 | 2023-2025 | Ocaliva |
| Boston Scientific Corporation | $47.91 | 2019-2023 | |
| Fujifilm Healthcare Americas Corporation | $33.91 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $31.22 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $30.83 | 2022-2024 | Dificid |
| Shire North American Group INC | $28.53 | 2019 | |
| Genzyme Corporation | $22.64 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $21.48 | 2024 | Injectafer |
| Aimmune Therapeutics, INC. | $20.95 | 2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $20.58 | 2025 | Dupixent |
| Janssen Biotech, INC. | $19.49 | 2023 | Simponi, Simponi Aria, Stelara |
| Alnylam Pharmaceuticals INC. | $17.12 | 2022 | |
| Redhill Biopharma INC. | $15.03 | 2023 | |
| Gilead Sciences, INC. | $14.33 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.08 | 2022 | |
| Braintree Laboratories, INC. | $12.37 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$41,161.77 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernest Weeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.